Exelixis, Inc. (EXEL)
| Market Cap | 5.24B |
| Revenue (ttm) | 1.03B |
| Net Income (ttm) | 64.77M |
| Shares Out | 313.39M |
| EPS (ttm) | 0.21 |
| PE Ratio | 81.61 |
| Forward PE | 50.51 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $16.73 |
| Previous Close | $16.94 |
| Change ($) | -0.21 |
| Change (%) | -1.24% |
| Day's Open | 17.06 |
| Day's Range | 16.58 - 17.06 |
| Day's Volume | 1,097,313 |
| 52-Week Range | 16.24 - 27.35 |
You don't need a lot of cash to begin or further your trek toward financial independence.
The market may have overreacted to weak clinical trial data, but its pessimism wasn't entirely misplaced.
The biotech stock plunged after disappointing clinical results.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the company's Executive Vice President, Scientific Strategy and Chief Scientific Officer, will pre...
You don't need to start with a fortune to make one on Wall Street.
The stock price of Exelixis, a genomics-based pharmaceuticals company focused on oncology treatments, has seen a large 21% drop over the last five trading days, after the company announced a negative ou...
Exelixis (EXEL) and partner announce unimpressive data from the late-stage COSMIC-312 study in patients with previously untreated advanced hepatocellular carcinoma.
The company reported successful clinical trial results, but investors were still disappointed.
Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (Cabometyx) in combination with Roche Holding AG's Tecen...
ALAMEDA, Calif. & PARIS--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced that, effective today, Gisela M. Schwab, M.D., the company's President, Product Development and Medical Affairs and Chief Medica...
You don't need a boatload of money to chart a path to financial freedom.
Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE: BMY) for STELLAR-002, a new p...
ALAMEDA, Calif. & PARIS--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results from the phase 3 COSMIC-311 pivotal trial of cabozantinib (CA...
R&D spending is hurting earnings, but long-term investors shouldn't be worried.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from a post-hoc exploratory analysis demonstrating that the efficacy benefits seen in the phase 3 CheckMate -9ER t...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from a post-hoc analysis of the phase 3 CheckMate -9ER trial demonstrating that CABOMETYX® (cabozantinib) in combi...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced promising phase 2 results for CABOMETYX® (cabozantinib) in combination with Bristol Myers Squibb's OPDIVO® (nivolumab) in ...
One is growing revenue. And the other may soon launch its first product.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following virtual investor confere...
Patient investors should make bank from this diverse collection of high-quality businesses.
Exelixis (EXEL) announces encouraging results from the cohort 6 of a phase Ib study of Cabometyx in combination with Tecentriq.
Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination with Roche's Tecentriq (atezolizumab) in patients with...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from the metastatic castration-resistant prostate cancer (CRPC) cohort 6 of COSMIC-021, the phase 1b trial of cabo...
Revenue growth will probably accelerate soon, but it might not be enough.
All three healthcare stocks could have solid growth prospects.
With the trading day about halfway over, the markets were somewhat mixed on Tuesday.
Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.
You don't need a lot of cash to begin building wealth on Wall Street.
Exelixis (EXEL) delivered earnings and revenue surprises of -100.00% and 0.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Exelixis (NASDAQ:EXEL) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 52.63% over the past year to $0.09, which beat th...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2021 and provided an update on progress toward achieving key corporate objective...
ALAMEDA, Calif. & TOULOUSE, France--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and GamaMabs Pharma SA today announced that they have entered into an agreement under which Exelixis will, upon the fut...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will participate in fireside chats ...
They're generating revenue now -- and more is on the way.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 after the markets close. At 5:00 p...
These fast-paced companies are on the leading edge of innovation.
The FDA accepts Exelixis' (EXEL) IND for XB002 in patients with advanced solid tumors and a phase I study is expected to start in the second quarter.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate t...
Exelixis' (EXEL) partner Ipsen secures an approval from the regulatory body in Europe for the combination of Cabomteyx and Opdivo to treat first-line RCC.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) in combination with OP...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that COSMIC-313, the phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX®), nivolumab (OPDIVO®) an...
Searching for drug developers that are innovative, but come with relatively low risk? Look no further.
Exelixis (EXEL) signs a collaboration and supply agreement with Merck KGaA and Pfizer to investigate XL092 in combination with Bavencio for treating various forms of urothelial carcinoma.
Exelixis Inc (NASDAQ: EXEL) has announced a clinical trial collaboration and supply agreement with Germany's Merck KGaA and Pfizer Inc (NYSE: PFE) for the ongoing Phase 1b dose-escalation study STELLAR-...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for the ongoing phase 1b...
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
ALAMEDA, Calif. & SHANGHAI--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics (“WuXi Bio”) (2269.HK) today announced the companies have entered into an exclusive license agreement to sup...
About EXEL
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, inclu... [Read more...]
| Industry Biotechnology | IPO Date Apr 7, 2000 |
| Stock Exchange NASDAQ | Ticker Symbol EXEL |
Financial Performance
In 2020, Exelixis's revenue was $987.54 million, an increase of 2.04% compared to the previous year's $967.78 million. Earnings were $111.78 million, a decrease of -65.18%.
Analyst Forecasts
According to 13 analysts, the average rating for Exelixis stock is "Buy." The 12-month stock price forecast is 29.93, which is an increase of 78.90% from the latest price.